1. Home
  2. RBCAA vs MESO Comparison

RBCAA vs MESO Comparison

Compare RBCAA & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RBCAA
  • MESO
  • Stock Information
  • Founded
  • RBCAA 1974
  • MESO 2004
  • Country
  • RBCAA United States
  • MESO Australia
  • Employees
  • RBCAA N/A
  • MESO N/A
  • Industry
  • RBCAA Major Banks
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • RBCAA Finance
  • MESO Health Care
  • Exchange
  • RBCAA Nasdaq
  • MESO Nasdaq
  • Market Cap
  • RBCAA 1.3B
  • MESO 1.3B
  • IPO Year
  • RBCAA 1998
  • MESO N/A
  • Fundamental
  • Price
  • RBCAA $70.45
  • MESO $19.49
  • Analyst Decision
  • RBCAA Hold
  • MESO Buy
  • Analyst Count
  • RBCAA 1
  • MESO 2
  • Target Price
  • RBCAA N/A
  • MESO $24.00
  • AVG Volume (30 Days)
  • RBCAA 25.7K
  • MESO 310.2K
  • Earning Date
  • RBCAA 10-17-2025
  • MESO 08-28-2025
  • Dividend Yield
  • RBCAA 2.54%
  • MESO N/A
  • EPS Growth
  • RBCAA 27.69
  • MESO N/A
  • EPS
  • RBCAA 6.28
  • MESO N/A
  • Revenue
  • RBCAA $369,212,000.00
  • MESO $17,198,000.00
  • Revenue This Year
  • RBCAA $15.62
  • MESO $288.50
  • Revenue Next Year
  • RBCAA N/A
  • MESO $167.17
  • P/E Ratio
  • RBCAA $11.30
  • MESO N/A
  • Revenue Growth
  • RBCAA 16.32
  • MESO 191.39
  • 52 Week Low
  • RBCAA $56.79
  • MESO $7.09
  • 52 Week High
  • RBCAA $80.68
  • MESO $22.00
  • Technical
  • Relative Strength Index (RSI)
  • RBCAA 38.51
  • MESO 68.32
  • Support Level
  • RBCAA $70.00
  • MESO $17.10
  • Resistance Level
  • RBCAA $72.48
  • MESO $18.91
  • Average True Range (ATR)
  • RBCAA 1.11
  • MESO 0.50
  • MACD
  • RBCAA -0.43
  • MESO 0.33
  • Stochastic Oscillator
  • RBCAA 5.41
  • MESO 85.25

About RBCAA Republic Bancorp Inc.

Republic Bancorp Inc operates as a financial institution that provides both traditional and non-traditional banking products through five reportable segments. It has traditional banking which generates the majority of revenue, Warehouse Lending, Tax Refund Solutions (TRS), Republic Payment Solutions segment, and Republic Credit Solutions (RCS) business segments. The business activities of these segments include retail mortgage and commercial lending, construction and land development lending, internet lending, correspondent and indirect lending and also private banking, treasury management services, internet, and mobile banking, bank acquisitions, short-term revolving credit facilities, fixed-term residential real estate loans and receipt and payment of federal.

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Share on Social Networks: